Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

October 4th 2024

The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC.

Neoantigen-Directed GRANITE Immunotherapy Improves PFS as Maintenance in MSS mCRC

October 2nd 2024

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

Dr Eng on Unmet Needs Within the mCRC Treatment Paradigm

September 30th 2024

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

Dr Ng on Factors That Influence Later-Line Treatment Decisions in mCRC

September 30th 2024

Kimmie Ng, MD, MPH, discusses factors of consideration for later-line treatment decisions in patients with refractory metastatic colorectal cancer.

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors

September 27th 2024

The MEK inhibitor PAS-004 is safe, tolerable, and generated early efficacy signals in patients with MAPK pathway–driven advanced cancers.

Dr Ng on the Addition of Vitamin D to Bevacizumab Plus Chemotherapy in mCRC

September 26th 2024

Kimmie Ng, MD, MPH, discusses the addition of vitamin D to standard chemotherapy plus bevacizumab in patients with untreated metastatic colorectal cancer.

Fixed-Dose Favezelimab Combo Fails to Improve OS in Pretreated, PD-L1+, MSS mCRC

September 25th 2024

The combination of favezelimab and pembrolizumab failed to improve OS vs regorafenib or TAS-102 in pretreated patients with PD-L1–positive, MSS mCRC.

Japan’s MHLW Approves Fruquintinib in Pretreated mCRC After Chemotherapy

September 24th 2024

Japan’s Ministry of Health, Labour, and Welfare approved fruquintinib in metastatic colorectal cancer following progression with chemotherapy.

GCC19CART Is Safe, Shows Clinical Activity in GCC+ R/R Metastatic Colorectal Cancer

September 23rd 2024

The CAR T-cell therapy GCC19CART was safe and showed clinical activity in relapsed/refractory metastatic colorectal cancer.

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

September 16th 2024

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Nonoperative Management Maintains DFRS, Promotes Organ Preservation in pMMR Rectal Cancer

September 16th 2024

In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.

Ramucirumab Plus TAS-102 Fails to Improve OS in Heavily Pretreated mCRC

September 15th 2024

Ramucirumab plus trifluridine/tipiracil failed to improve overall survival vs TAS-102 alone in patients with heavily pretreated metastatic colorectal cancer.

FOLFIRI Plus Encorafenib and Cetuximab Is Active in BRAF V600E–Mutant mCRC

September 15th 2024

Encorafenib, cetuximab, and FOLFIRI demonstrate promising antitumor activity in patients with BRAF V600E-mutant metastatic colorectal cancer.

Frontline Zanidatamab Plus Chemo ± Bevacizumab Is Safe, Active in HER2+ mCRC

September 14th 2024

Zanidatamab plus chemotherapy with or without bevacizumab showed efficacy and safety in previously untreated HER2-positive metastatic colorectal cancer.

Dr Kim on the Safety of NT-17 Plus Pembrolizumab in Pretreated CRC and PDAC

September 11th 2024

Richard Kim, MD, discusses the safety of NT-17 and next steps for its evaluation in pretreated microsatellite stable CRC and PDAC.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment

September 1st 2024

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued

August 30th 2024

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Dr Dasari on Salvage Treatment Considerations for Unresectable Metastatic CRC

August 30th 2024

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Fruquintinib Represents a Novel Therapeutic Approach in Advanced mCRC

August 30th 2024

Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for patients with advanced metastatic colorectal cancer.